SG11201901203PA - Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients - Google Patents
Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patientsInfo
- Publication number
- SG11201901203PA SG11201901203PA SG11201901203PA SG11201901203PA SG11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- treatment
- new york
- antibodies
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER (19) World Intellectual Property Organization International Bureau (43) International Publication Date .....0\"\" 22 February 2018 (22.02.2018) WIP0 I PCT THE PATENT COOPERATION TREATY (PCT) 111111111111111111 11111111110111110100111111011100H011111101111111011110111111 (10) International Publication Number WO 2018/035001 Al _ (51) (21) (22) (25) Filing Language: (26) (30) (71) (71) International Patent Classification: C07K 16/28 (2006.01) International Application Number: (72) PCT/US2017/046668 International Filing Date: (74) 13 August 2017 (13.08.2017) English (81) Publication Language: English Priority Data: 62/374,752 13 August 2016 (13.08.2016) US Applicant (for AM, AZ, BY CN, ID, IN, JP, KG, KR, KZ, MD, RU, SG, TH, TJ, TM only): UNITED BIOMEDICAL, INC. [US/US]; 25 Davids Drive, Hauppauge, New York 11788 (US). Applicant (for US only): UBI US HOLDINGS, LLC. [US/US]; 25 Davids Drive, Hauppauge, New York 11788 (84) (US). Applicant (for all designated States except AM, AZ, BY, CN, ID, IN, JP, KG, KR, KZ, RU, SG, TH, TJ, TM): UBI (71) IP HOLDINGS; c/o Stuarts Corporate Services Ltd., P.O. Box 2510, Grand Cayman, KY1-1104 (KY). Inventor: WANG, Chang Yi; 47 Snake Hill Road, Cold Spring Harbor, New York 11724 (US). Agent: FILL, Peter et al.; Locke Lord LLP, 3 World Fi- nancial Center, New York, New York 10281 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = Title: TREATMENT AND SUSTAINED VIROLOGIC REMISSION STABILIZED PATIENTS Figure 21 (54) HAART OF HIV INFECTION BY ANTIBODIES TO CD4 IN = = f Treatment with UB-421-like : .• antibodies = — = T cal, tore HIV- antiapn specific 1 Celt activity Triggeetof latency itctivatitm Reduce reservoirs ---- Prevent esti- Actively fn-cell and infected cell-free Released cells inrk (11011t viral particle U8421 coated cells : The present disclosure is directed to compositions and methods for the prevention, treatment, and/or functional cure of infection. One aspect of the present disclosure relates to monoclonal antibodies directed against CD4, compositions thereof, and employing such compositions for the prevention, treatment, and functional cure of HIV infection. \" methods = = — = = = = — = _ fl fl C= C= 11 in en © ,-1 (57) 0 HIV C [Continued on next page] WO 2018/035001 Al MIDEDIMOMOIDEIREEMODHOMINIMMOVOIME TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662374752P | 2016-08-13 | 2016-08-13 | |
PCT/US2017/046668 WO2018035001A1 (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901203PA true SG11201901203PA (en) | 2019-03-28 |
Family
ID=61197201
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100268RA SG10202100268RA (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
SG11201901203PA SG11201901203PA (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100268RA SG10202100268RA (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Country Status (14)
Country | Link |
---|---|
US (1) | US11292839B2 (en) |
EP (1) | EP3497133A4 (en) |
JP (1) | JP2019534891A (en) |
KR (1) | KR20190071677A (en) |
CN (1) | CN109996815A (en) |
AU (1) | AU2017312887A1 (en) |
BR (1) | BR112019002734A2 (en) |
CA (1) | CA3033728A1 (en) |
MX (1) | MX2019001814A (en) |
RU (1) | RU2019106804A (en) |
SG (2) | SG10202100268RA (en) |
TW (1) | TW201808998A (en) |
WO (1) | WO2018035001A1 (en) |
ZA (1) | ZA201901374B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11292839B2 (en) * | 2016-08-13 | 2022-04-05 | Ubi Us Holdings, Llc | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients |
AU2020275049A1 (en) * | 2019-05-16 | 2022-01-06 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells comprsing a recognition molecule |
EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
DE3828582A1 (en) | 1988-08-23 | 1990-03-01 | Max Planck Gesellschaft | MONOCLONAL ANTIBODY TO INHIBIT THE INFECTION OF CELLS BY HIV VIRUSES |
EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
JPH0725794B2 (en) | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | Novel peptide |
US5871732A (en) | 1990-11-27 | 1999-02-16 | Biogen, Inc. | Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
JPH06125783A (en) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | Recombinant anti-hiv antibody and its preparation |
DK0746613T3 (en) | 1994-03-08 | 2006-09-25 | Sloan Kettering Inst Cancer | Recombinant humanized antibodies to FB5 |
US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
US5962319A (en) | 1997-05-19 | 1999-10-05 | Bml, Inc. | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene |
JP3231262B2 (en) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | Human Th1-specific protein, gene encoding the same, and transformants, recombinant vectors and antibodies related thereto |
JPH10155489A (en) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | Recombinant antibody and nucleic acid coding for the same |
ES2258817T3 (en) | 1997-05-21 | 2006-09-01 | Biovation Limited | METHOD FOR THE PRODUCTION OF NON-IMMUNOGEN PROTEINS. |
WO1999061629A1 (en) | 1998-05-25 | 1999-12-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Cell separation device and separation method |
US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
AR029337A1 (en) | 1999-03-02 | 2003-06-25 | Schering Corp | USE OF INTERFERON ALFA PEGILADO FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THERAPY AGAINST HIV |
DK1454137T3 (en) | 2001-12-11 | 2008-06-16 | Biotectid Gmbh | Use of a labeled ligand with specificity for the human CD4 molecule |
JP2003327536A (en) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | Infection and growth inhibitor of human immunodeficiency syndrome virus |
US20030211470A1 (en) | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
EP1879617A1 (en) | 2005-05-02 | 2008-01-23 | Mymetics Corporation | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 |
RU2393873C2 (en) | 2005-05-02 | 2010-07-10 | Майметикс Корпорейшн | Antibody or fragment thereof, having neutralising effect on hiv, but not on il2 |
WO2007025276A2 (en) | 2005-08-25 | 2007-03-01 | Government Of The United States Of America, As Represented By The Secretary | Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies |
WO2007094983A2 (en) | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
CA2884430A1 (en) | 2012-09-07 | 2014-03-13 | Baylor Research Institute | Hiv vaccine compositions and methods |
MX2015012709A (en) | 2013-03-14 | 2016-05-31 | Macrogenics Inc | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor. |
CA2913231A1 (en) * | 2013-05-24 | 2014-11-27 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
EP3194442A4 (en) * | 2014-09-16 | 2018-05-23 | UBI IP Holdings | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
US11292839B2 (en) * | 2016-08-13 | 2022-04-05 | Ubi Us Holdings, Llc | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients |
-
2017
- 2017-08-13 US US16/325,361 patent/US11292839B2/en active Active
- 2017-08-13 MX MX2019001814A patent/MX2019001814A/en unknown
- 2017-08-13 RU RU2019106804A patent/RU2019106804A/en not_active Application Discontinuation
- 2017-08-13 SG SG10202100268RA patent/SG10202100268RA/en unknown
- 2017-08-13 AU AU2017312887A patent/AU2017312887A1/en active Pending
- 2017-08-13 KR KR1020197007296A patent/KR20190071677A/en not_active Application Discontinuation
- 2017-08-13 EP EP17841919.8A patent/EP3497133A4/en active Pending
- 2017-08-13 JP JP2019529466A patent/JP2019534891A/en active Pending
- 2017-08-13 BR BR112019002734-3A patent/BR112019002734A2/en unknown
- 2017-08-13 CN CN201780050119.1A patent/CN109996815A/en active Pending
- 2017-08-13 SG SG11201901203PA patent/SG11201901203PA/en unknown
- 2017-08-13 CA CA3033728A patent/CA3033728A1/en active Pending
- 2017-08-13 WO PCT/US2017/046668 patent/WO2018035001A1/en unknown
- 2017-08-14 TW TW106127443A patent/TW201808998A/en unknown
-
2019
- 2019-03-05 ZA ZA2019/01374A patent/ZA201901374B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201901374B (en) | 2022-04-28 |
AU2017312887A1 (en) | 2019-03-07 |
RU2019106804A (en) | 2020-09-21 |
EP3497133A4 (en) | 2020-03-25 |
US20190194326A1 (en) | 2019-06-27 |
WO2018035001A1 (en) | 2018-02-22 |
KR20190071677A (en) | 2019-06-24 |
CN109996815A (en) | 2019-07-09 |
RU2019106804A3 (en) | 2021-03-29 |
CA3033728A1 (en) | 2018-02-22 |
US11292839B2 (en) | 2022-04-05 |
TW201808998A (en) | 2018-03-16 |
BR112019002734A2 (en) | 2019-05-14 |
JP2019534891A (en) | 2019-12-05 |
EP3497133A1 (en) | 2019-06-19 |
MX2019001814A (en) | 2019-07-08 |
SG10202100268RA (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901203PA (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201909547TA (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201901950TA (en) | Methods of treating immune disorders using pd-1 binding proteins | |
SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |